2013-11-14T10:17:34-08:00 2012-12-31 Regalia & Associates CPAs 103 Town Country Dr Ste K Danville CA 94526 990 2012-01-01 651230251 THE CANARY FUND DBA CANARY FOUNDATION CANA 6505215665 3155 Porter Drive Palo Alto CA 94304 Ronica Smucker 2013-11-14 true Douglas W Regalia P00186389 9253140390 2012 2016-02-25 16:41:14Z X Don Listwin 3155 Porter Drive Palo Alto CA 94304 10619493 false false X www.canaryfoundation.org X 2004 CA Canary Foundation is the world's first non-profit organization dedicated solely to the funding, discovery and development of tests for early cancer detection. 6 6 7 0 11328418 9959117 0 -11240 -807 478709 130073 11795887 10088383 2424216 16573859 0 878778 764302 0 464644 445513 498477 3748507 17836638 8047380 -7748255 12752705 15273665 12003219 22421526 749486 -7147861 X Canary Foundation is a public charity exempt from U.S. federal income tax under Section 501(c)(3) of the Internal Revenue Code in the United States. Canary Foundation of Canada is a Public Foundation registered with the Canada Revenue Agency; Business Number 82906 8550 RROOO1.The Canary Foundation has assembled teams of cancer researchers recognized by their peers as leaders in their disciplines from across multiple institutions and disciplines to attack the problem of early detection in a new, collaborative, action-oriented manner with the foremost objective of translating research into clinical applications. Canary differentiators include: * Dedication to early detection * Leaders in collaborative science * Focused and managed research * Best-in-class talent * 100% of donations goes to researchOne of the first decisions the Science Team made was to choose ovarian cancer as a prototype for creating an early detection blood test to detect trace amounts of proteins called biomarkers pro false false 16984506 16573859 Canary Scientific ProgramsThe goals of the program are to develop tests that can: 1) Identify lethal prostate cancers at an early (curable) stage; 2) Classify prostate cancers as either 1) potentially lethal; best treated with aggressive therapy b) non-lethal: suitable for continued monitoring without aggressive treatment. Given the large body of published but unvalidated candidate markers for prostate cancer, we focus efforts on evaluating the performance of a selected set of promising biomarkers. Candidate biomarkers are evaluated based on ability to detect lethal prostate cancers at an early (curable) stage and to discriminate lethal from non-lethal prostate cancer. We focus on blood-based biomarkers for early detection and considering both blood-based and tissue-based biomarkers for prognostic applications. CANARY OVARIAN CANCER PROGRAMThe goal of our ovarian research program is to develop a strategy to accurately identify ovarian cancers that would otherwise be lethal at a stage when they are readily curable. Our vision is of a two-stage screening strategy, consisting of a simple blood test followed by a molecular imaging test. Development of blood and imaging tests follows a similar roadmap; both include biomarker discovery followed by validation, but they also involve different techniques and challenges.CANARY LUNG CANCER PROGRAMCanary is focused on developing diagnostics with high sensitivity and specificity to detect otherwise lethal lung cancers at a stage when they are readily curable. To this end, Canary has assembled a team of experts who are collaborating to discover and validate biomarkers for blood and imaging tests that together will identify individuals harboring lethal lung cancers so that they can be removed. We plan to follow up on our research by rapidly propelling effective early detection cancer tests into the hands of clinical providers so that patients can begin to benefit as soon as possible. The Canary Lung Cancer Program supports the development and maintenance of critical biospecimen resources, blood biomarker discovery and validation, molecular imaging projects for early detection of lethal lung cancer, and epidemiology and modeling for effective lung cancer screening. 16984506 true true false false false false false false false false true false false false false true true false false false false true false false true false false true false true false false false false false false false false false false false true false false false false false false false false false true 6 0 true 7 true false false true CA false false true true false false 0 false false false false false false false false false false X 6 6 false false true false false false false true true false false true true true true true true true true false CA X X Theresa McCann Office Manager 6505215665 3155 Porter Drive Palo Alto CA 94304 Hilary Valentine 4.00 0.00 X 0 0 0 Kevin Kennedy 4.00 0.00 X 0 0 0 Michael Ball 4.00 0.00 X 0 0 0 Michael Ashby 4.00 0.00 X 0 0 0 Dale Jantzen 4.00 0.00 X 0 0 0 Rob Lynch 4.00 0.00 X 0 0 0 Don Listwin 8.00 0.00 X X 0 0 0 Ronica Smucker 40.00 0.00 X 220015 0 28487 Therese Quinlan 40.00 0.00 X 144000 0 12293 364015 40780 2 false true false 0 9959117 88854 9959117 0 200 200 0 0 0 128111 127261 1857 850 -1857 -1007 -1007 532065 401992 130073 0 0 0 10088383 -1007 200 16494798 16494798 0 79061 79061 0 220015 52029 73425 94561 0 371143 87768 123859 159516 0 129705 30673 43286 55746 43439 10272 14497 18670 0 2035 2035 27458 27458 0 0 0 41536 13920 27616 43636 43636 18395 159 5219 13017 12845 3885 8960 0 31279 12977 18302 0 0 124962 123149 1813 14 14 0 17596 9519 8077 0 Bank and credit card charges 18752 18752 Travel, hotels, meals 33471 31322 2149 Miscellaneous 44222 2723 41499 Donations/Gifts/Awards 46423 46423 35853 2471 22999 10383 17836638 16984506 387488 464644 563710 749771 2288829 2118844 9801362 12315940 0 0 0 0 0 26123 27507 102382 40779 72681 61603 0 0 0 0 0 12752705 15273665 99734 67356 11903485 22354170 12003219 22421526 X -9074826 -19380479 9824312 12232618 749486 -7147861 12752705 15273665 X -7748255 -149092 X false true X true false X 1367736 2355475 6808290 11328418 9959117 31819036 0 0 1367736 2355475 6808290 11328418 9959117 31819036 4990005 26829031 27367 916 484 -9512 1050 20305 0 -2511 -1728 -1857 -6096 31833245 0.84280 0.85850 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 67145 67145 35237 40779 -5542 61603 X 10341283 252900 252900 10088383 10088383 18238630 401992 401992 17836638 17836638 Part XII, Line 2d Part XII, Line 2d: Other expenses and losses per audited F/S Special Events expenses $401992 Part XI, Line 2d Part XI, Line 2d: Other revenue amounts included in F/S but not included on form 990 Special Events expenses $401992 Change in value of long-term pledges rec $-149092 Part X Part X : FIN48 Footnote Income TaxesFinancial statement presentation follows the recommendations of ASC 740, Income Taxes. Under ASC 740, the Fund is required to report information regarding its exposure to various tax positions taken by the Fund and requires a two-step process that separates recognition from measurement. The first step is determining whether a tax position has met the recognition threshold; the second step is measuring a tax position that meets the recognition threshold. Management believes that the Fund has adequately evaluated its current tax positions and has concluded that as of December 31, 2012, the Fund does not have any uncertain tax positions for which a reserve or an accrual for a tax liability would be necessary.The Fund has received notification from the Internal Revenue Service and the State of California that it qualifies for tax-exempt status under Section 501(c)(3) of the Internal Revenue Code and Section 23701d of the California Revenue and Taxation Code. The exemptions are subject to periodic review by the federal and state taxing authorities and management believes that the Fund continues to satisfy all federal and state statutes in order to qualify for continued tax exemption status. true United Kingdom Cancer Rsrch 11645 Canada Cancer Rsrch 67416 2 false false false false false false Grantmaker's Description of How Grants are Used in Foreign Country Once grants are approved, recipient organization must acknowledge the terms of the grant and reporting schedule. A budget is prepared in advance of all international grants. Financial and Narrative Reports are required at least once at the end of the project period. Expenditures are made in accordance with approved grant disbursements by the Board of Directors. Discussions, e-mails, and other techniques of communication are employed to ensure that funds are utilized according to the original intent. Accomplishments are documented in writing and submitted to the organization's head office. X X X X X false Fall Fundraiser 273738 273738 12335 17159 1669 43088 Bike Challenge 177930 177930 36207 2413 19276 12324 135063 2 80397 80397 14877 10451 42097 1750 53283 532065 532065 51084 25199 78532 15743 231434 401992 130073 true University of Washington 1959 NE Pacific Seattle WA 98195 943079432 501c3 406206 0 Pancreas Cancer BioMarkers University of Texas Health Sc 7703 Floyd Curl Drive San Antonio CA 78229 237232618 501c3 63000 0 Cancer Research University of Texas 800 West Campbell Road Richardson TX 75080 237232618 501c3 255000 0 Cancer Research University of Michigan 648 N Shaw Lane Room East Lansing MI 48824 381358000 501c3 30000 0 Cancer Research UCSF Foundation 500 Parnassus MU-200W Box 0244 San Francisco CA 94143 942829914 501c3 95800 0 Cancer Research Stanford University 450 Serra Mall Stanford CA 94305 946174066 501c3 15000000 0 Cancer Research Stanford Univ Fdtn 300 Pasteur Drive Stanford CA 97305 946174066 501c3 492392 0 Cancer Research Stanford School Of Medicine 291 Campus Drive Stanford CA 94305 946174066 501c3 225480 0 Cancer Research Seattle Inst Biomedical Clinical 1660 S Columbian Way S-151F Seattle WA 98108 911452438 501c3 52756 0 Cancer Research Purdue University 610 Purdue Mall Hovde West Lafayette IN 47907 356002041 501c3 10000 0 Cancer Research Mount Sinai School Medicine 1428 Madison Avenue New York NY 10029 136171197 501c3 45000 0 Cancer Research Eastern VA Medical School PO Box 5 Norfolk VA 23501 237053028 501c3 34600 0 Cancer Research Beth Israel Deaconess Medical 330 Brookline Avenue Boston MA 02215 042103881 501c3 48800 0 Cancer Research 13 0 Grantmaker's Description of How Grants are Used The Canary Fund requires ongoing feedback in the form or oral and written reports in order to monitor the progress of each grant funded for approval. X X X X false false false false false false false false false false Therese Quinlan 144000 12293 156293 Ronica Smucker 220015 28487 220015 28487 X 3 123259 FMV X Other 1 7552 FMV X Wine for luncheon event 1 6316 FMV X Donated Wine for Events 1 74986 FMV false false false Form 990, Part XI, Line 9 Other Changes In Net Assets Or Fund Balances - Other Decreases Change in value of long-term pledges receivable = -$149092 Form 990, Part VI, Line 19 Form 990, Part VI, Line 19: Other Organization Documents Publicly Available ALL OF THE ORGANIZATION'S GOVERNING DOCUMENTS, FINANCIAL STATEMENTS AND OTHER LEGALFILINGS ARE MAINTAINED IN A SECURE ENVIRONMENT AND HELD AVAILABLE FOR INSPECTION BYTAX AUTHORITIES AND THE GENERAL PUBLIC. TAX RETURNS ARE POSTED ANNUALLY TOWWW.GUIDESTAR.ORG (WHERE IT IS AVAILABLE FOR VIEWING AS AN ELECTRONIC COPY) AND ARE ALSO AVAILABLE AT THE ORGANIZATION'S OFFICE IN PALO ALTO, CALIFORNIA (FOR A PHYSICAL INSPECTION). Form 990, Part VI, Line 15b Form 990, Part VI, Line 15b: Compensation Review and Approval Process for Officers and Key Employees COMPENSATION OF OTHER HIGH-LEVEL PERSONNEL AND KEY EMPLOYEES IS REVIEWED AT LEAST ANNUALLY BY MEMBERS OF MANAGEMENT. EFFORTS ARE MADE TO SECURE COMPENSATION DATA FROM INDUSTRY SOURCES IN ORDER TO DETERMINE COMPETITIVENESS AND APPROPRIATENESS OF SALARIES AND ALL RELATED BENEFITS. ALL DECISIONS ARE THEN DOCUMENTED IN PERSONNEL FILES. Form 990, Part VI, Line 15a Form 990, Part VI, Line 15a: Compensation Review & Approval Process - CEO, Top Management MEMBERS OF THE BOARD OF DIRECTORS REVIEW THE COMPENSATION OF ALL HIGH-LEVEL PERSONNEL ANNUALLY IN ACCORDANCE WITH IRS RULES AND REGULATIONS. EFFORTS ARE MADE TO SECURE COMPENSATION DATA FROM INDUSTRY SOURCES IN ORDER TO DETERMINE COMPETITIVENESS AND APPROPRIATENESS OF SALARIES. EVERY EFFORT IS MADE TO ENSURE THAT THE PROCESS IS THOROUGH AND TRANSPARENT IN ACCORDANCE WITH IRS GUIDELINES AND THE ORGANIZATION'S POLICIES AND PROCEDURES. Form 990, Part VI, Line 12c Form 990, Part VI, Line 12c: Explanation of Monitoring and Enforcement of Conflicts MEMBERS OF THE BOARD OF DIRECTORS REVIEW ALL POTENTIAL CONFLICTS OF INTEREST ATLEAST ANNUALLY. THE EXECUTIVE DIRECTOR AND ALL BOARD MEMBERS ARE REQUIRED TO DISCLOSE (IN WRITING) POTENTIAL CONFLICTS AND ANY RELATED PARTY AFFILIATIONS. LOANS BETWEEN THE ORGANIZATION AND MEMBERS OF MANAGEMENT AND THE BOARD ARE STRICTLY PROHIBITED. THE ORGANIZATION SEEKS FULL TRANSPARENCY ON ALL RELATIONSHIPS. ANY POTENTIAL CONFLICTS (IN FACT OR APPEARANCE) ARE DISCUSSED OPENLY AND RESOLVED IN ACCORDANCE WITH THE ORGANIZATION'S POLICIES AND PROCEDURES. Form 990, Part VI, Line 11b Form 990, Part VI, Line 11b: Form 990 Review Process FORM 990 IS PREPARED BY AN OUTSIDE TAX PROFESSIONAL. THE FORM IS THEN REVIEWED BYTHE ORGANIZATION'S MANAGEMENT AND A MEMBER OF THE BOARD OF DIRECTORS. THIS GROUP OF INDIVIDUALS THEN DISCUSSES THE CONTENTS OF THE RETURN WITH THE OUTSIDE TAX PROFESSIONAL. AFTER A FULL REVIEW (WITH MODIFICATIONS WHERE NECESSARY), THE FINAL VERSION OF THE TAX RETURN IS PROVIDED TO ALL MEMBERS OF THE ORGANIZATION'S VOTING BODY. A REPRESENTATIVE OF MANAGEMENT SIGNS AND MAILS THE RETURN TO THE DEPARTMENT OF THE TREASURY. Form 990, Part VI, Line 4 Form 990, Part VI, Line 4: Description of Significant Changes to Organizational Documents The Canary Fund amended its By-Laws to increase the number of directors.A copy of the amendment is included with this tax return. Form 990, Part VI, Line 1a Form 990, Part VI, Line 1a: Explanation of Delegated Broad Authority to Committee In accordance with common practice in the nonprofit community, the Board delegates certain matters to The Executive Committee, which is empowered to act between board meetings if necessary, and sometimes with specifically delegated authority to act in particular areas on behalf of the full board. Form 990, Part III, Line 4d Form 990, Part III, Line 4d: Other Program Services Description OTHER PROGRAM SERVICES 4: CANARY PROSTATE CANCER PROGRAMThe specific goals of the Canary Foundation Prostate program are to develop tests that can: 1) Identify lethal prostate cancers at an early (curable) stage; 2) Classify prostate cancers as either 1) potentially lethal; best treated with aggressive therapy b) non-lethal: suitable for continued monitoring without aggressive treatment. Given the large body of published but unvalidated candidate markers for prostate cancer, we are focusing our initial efforts on evaluating the performance of a selected set of promising biomarkers. Candidate biomarkers are evaluated based on their ability to detect lethal prostate cancers at an early (curable) stage and to discriminate lethal from non-lethal prostate cancer. We are focusing on blood-based biomarkers for early detection and considering both blood-based and tissue-based biomarkers for prognostic applications. OTHER PROGRAM SERVICES 5: CANARY PANCREATIC CANCER PROGRAMCanary is focused on developing diagnostics with high sensitivity and specificity to detect otherwise lethal pancreatic cancers at an early stage when they can be cured through surgical section. We anticipate that no single biomarker will be sufficient to create a test with the required sensitivity and specificity to detect pancreatic cancer early. Instead, a definitive diagnosis will rely upon combinations of biomarkers and upon blood and imaging tests used together. To this end, the Canary pancreatic cancer team is collaborating to discover and validate biomarkers that will provide the basis for blood and imaging tests for the early detection of pancreatic cancer. We plan to follow up our research by rapidly propelling effective early detection tests into the hands of clinical providers to that patients can begin t o benefit as soon as possible. OTHER PROGRAM SERVICES 6: CANARY COLLABORATIONS PROGRAMCanary Foundation believes that a collaborative, coordinated approach is necessary to achieve our goals. Our multi-disciplinary, multi-institutional Early Detection Program provides a great example of this philosophy in action. We created our Collaboration Program to foster this collaborative approach among the broader community of cancer researchers. We provide scientific program management to make sure that all funded research activities among the scientists and clinicians at the various partner institutions are on track and that any obstacles are rapidly addressed and overcome.The specific collaboration programs that we support include: national and international workshops and symposiums, a postdoctoral scientist training program, an online scientific journal, and joint projects with government and foundations. OTHER PROGRAM SERVICES 7: CANARY CENTER AT STANFORD FOR CANCER EARLY DETECTIONOn September 13, 2008, together with Dr. Bev Mitchell, Director of Stanford's Cancer Center, and Dr. Sanjiv (Sam) Gambhir, Director of Stanford's Molecular Imaging Programs (MIPS), Canary Foundation announced the creation of the Canary Center at Stanford. The Canary Center at Stanford will be the only facility in the world with dedicated full-time faculty focused on the early detection of cancer and will integrate both blood and imaging-based diagnostic research. This first class integrated facility will attract and develop the best minds in the world to the problem of cancer early detection. Operations will commence in the spring of 2009.The Canary Center at Stanford has secured a major portion of a 60,000-square-foot facility sponsored by the School of Medicine and the Department of Radiology. The Center will house multiple faculty devoted to early detection of cancer and over 100 research affiliates. Dr. Sanjiv (Sam) Gambhir will lead the Center as Scientific Director. The Center will be supported by research "cores" that provide scientific capabilities to the research teams. The four initial cores will be Chemistry, Proteomics, Bioinformatics, and Clinical Trials.The Canary Center at Stanford brings together multiple stakeholders, including the School of Medicine, the Radiology Department, the Cancer Center, and Canary Foundation. Canary Foundation has dedicated $25 million for start-up costs, including equipment, modest renovations to the existing research facility, staffing, and faculty recruitment. The Department of Radiology has committed to four new faculty members in molecular imaging, as well as $4 million to support faculty recruitment. The School of Medicine has also committed to four new faculty members for the Center and has committed to supporting facility renovations and lease costs. OTHER PROGRAM SERVICES 8: A Complete discussion of all of The Canary Foundation's program activities is provided below and continues on Schedule O. Total Expenditures Related to Program Activities amounted to $2,860,982.